|
業務類別
|
Biotechnology |
|
業務概覽
|
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC). |
| 公司地址
| 210 East Grand Avenue, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 457-2700 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.allogene.com |
| 員工數量
| 152 |
| Mr. Earl Douglas |
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary |
-- |
30/04/2026 |
| Mr. Geoffrey M. Parker |
Executive Vice President and Chief Financial Officer |
美元 500.00K |
30/04/2026 |
| Ms. Annie Yoshiyama |
Principal Accounting Officer, Senior Vice President and Corporate Controller |
-- |
12/03/2026 |
| Dr. Zachary Roberts, M.D.,PhD |
President and Chief Executive Officer |
美元 530.21K |
28/05/2026 |
| Mr. Benjamin Machinas Beneski |
Senior Vice President and Chief Technical Officer |
-- |
30/04/2026 |
|
|
| Dr. Arie S. Belldegrun, F.A.C.S.,M.D. |
Executive Chairman of the Board |
30/04/2026 |
| Mr. Joshua A. Kazam |
Director |
30/04/2026 |
| Dr. Vicki L. Sato, PhD |
Independent Director |
30/04/2026 |
| Dr. Franz Bernard Humer, PhD |
Lead Independent Director |
30/04/2026 |
| Dr. David D. Chang, M.D.,PhD |
Director |
28/05/2026 |
| Dr. Owen N. Witte, M.D. |
Independent Director |
30/04/2026 |
| Mr. John DeYoung |
Independent Director |
30/04/2026 |
| Ms. Deborah M. Messemer |
Independent Director |
30/04/2026 |
| Ms. Elizabeth Barrett |
Independent Director |
30/04/2026 |
| Dr. Stephen L. Mayo, PhD |
Independent Director |
30/04/2026 |
|
|
|
|
